<DOC>
	<DOCNO>NCT01606137</DOCNO>
	<brief_summary>Subjects previously receive GW-1000-02 GW study opt continue use long-term monitored ongoing tolerability evidence clinical benefit .</brief_summary>
	<brief_title>A Study Long-term Safety Sativex Use</brief_title>
	<detailed_description>Subjects previously participate placebo control GW clinical study screen eligible begin dose GW-1000-02 . Subjects review tolerability evidence clinical benefit week two four every eight week . Subjects self-titrated symptom resolution maximum tolerated/allowable dose 130 mg THC 120 mg CBD .</detailed_description>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Willing able give inform consent . Male female age 18 year . Diagnosed condition categorise one following : multiple sclerosis , spinal cord condition , peripheral nerve injury central nervous system damage associate vascular , traumatic , infective , genetic metabolic disease whose symptom ( ) wholly relieve currently available therapy , prior previous study GW100002 placebo . Had participate GW clinical study use GW100002 within previous month . Had show tolerability study medication previous GW study . Was expect , investigator , gain clinical benefit receive longterm GW100002 . Were willing , female child bear potential male subject partner child bear potential , ensure effective contraception use study three month thereafter . Had use cannabinoids ( cannabis , Marinol Nabilone ) least seven day Visit 1 ( exception GW100002 give study medication ) willing abstain use cannabis study . Recent ( within seven day ) haematology blood chemistry normal consider clinically acceptable view subject underlying condition . Able ( investigator opinion ) willing comply study requirement . Willing Home Office notify participation study . Willing allow general practitioner consultant , appropriate , notified participation study . History serious psychiatric illness , include schizophrenia , psychotic illness severe personality disorder depression associate underlying condition . Known strongly suspect alcohol substance abuse consider investigator risk alcohol substance abuse . Severe cardiovascular disorder , ischaemic heart disease , arrhythmia ( well control atrial fibrillation ) , poorly control hypertension severe heart failure . History epilepsy convulsion . Significant renal hepatic impairment . Terminally ill. Any significant disease disorder , opinion investigator , may either put subject risk participation study , may influence result study , subject 's ability participate study . Female subject pregnant , lactate plan pregnancy course study . Regular levodopa ( Sinemet , Sinemet Plus , Levodopa , Ldopa , Madopar , Benserazide ) therapy within seven day study entry . Known suspected hypersensitivity cannabinoids excipients study medication . Known suspected adverse reaction cannabinoids . Donation blood study . Previous participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>